Skip to content
close icon

Pulmonary Hypertension

NO LONGER ACCEPTING APPLICATIONS
Published on:
September 18, 2024
Sign-up Expiration:
December 17, 2024
Updated:
Topics:
Heart Health
Lung Health
Pulmonary Hypertension
Chest Pain
Dr. Naresh Mori
Locations:
Rock Hill, SC
Dr. Naresh Mori

The primary objective of this study is to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment. Additional safety, function and symptoms, hemodynamic, and biomarker assessments will also be performed, with key secondary endpoints assessed at baseline and after 12 and 24 weeks of treatment. Right heart catheterization (RHC) and echocardiograms will be performed at baseline and after 24 weeks of treatment.

View Additional Information
View Clinical Trial Attachment
Sign Up NowExpired - View Other Trials
ENDED
12/17/24

Other Enrolling Clinical Trials

View All Enrolling Trials
A Study To Look At Ways Of Treating Negative Symptoms Of Schizophrenia - CLICK

A study to evaluate the effectiveness and safety of a digital therapeutic (CT-155) as an adjunct to standard-of-car antipsychotic therapy in adult and late adolescent participants with experiential negative symptoms of schizophrenia.

View Trial
Sjögren Syndrome - RESOLVE

The purpose of the study is to evaluate the impact of RSLV-132 on dryness, tiredness/fatigue and pain in female participants with primary Sjögren's syndrome (pSS) with moderate to severe symptom burden and to assess its safety and tolerability.

View Trial
Asthma Clinical Trial - FLASH

The purpose of this study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma

View Trial
Adults with Active Psoriatic Arthritis and Obesity

This study is to find out if by lowering weight we can reduce the symptoms of Psoriatic Arthritis.

View Trial
Adults with Moderate-to-Severe Plaque Psoriasis and Obesity

This study to see if weight loss improves plaque psoriasis

View Trial
Severe Alopecia Areata

This study is to evaluate efficacy and safety of Upadacitinib (Rinvoq) in adult and adolescent subjects with severe Alopecia Areata (AA)

View Trial

Sign-Up, Make an Appointment, or Receive More Information

Thank you for your interest in our clinical research trials. Please enter your contact information below and someone will reach out to you shortly to see if you qualify. You can also call us at 1-800-785-3150 or email participate@onsiteclinical.com

By submitting this form, you are consenting to receive marketing emails from: OnSite Clinical Solutions, LLC, 11220 Elm Lane Suite 200 Charlotte, NC 28277, and will be able to revoke your consent to receive emails at any time.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.